Artivion, Inc. (NYSE:AORT) VP Matthew A. Getz Sells 1,157 Shares of Stock

Artivion, Inc. (NYSE:AORTGet Free Report) VP Matthew A. Getz sold 1,157 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $18.72, for a total transaction of $21,659.04. Following the completion of the transaction, the vice president now owns 48,503 shares of the company’s stock, valued at approximately $907,976.16. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Artivion Price Performance

NYSE:AORT opened at $19.75 on Friday. The company has a quick ratio of 3.43, a current ratio of 4.85 and a debt-to-equity ratio of 1.10. The firm has a market cap of $813.70 million, a PE ratio of -26.33 and a beta of 1.66. Artivion, Inc. has a 12 month low of $11.60 and a 12 month high of $20.49. The company’s 50-day moving average price is $18.35 and its two-hundred day moving average price is $16.65.

Artivion (NYSE:AORTGet Free Report) last announced its earnings results on Thursday, February 15th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.24. The business had revenue of $93.67 million for the quarter, compared to the consensus estimate of $89.75 million. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. On average, equities analysts anticipate that Artivion, Inc. will post 0.26 EPS for the current fiscal year.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp bought a new position in Artivion in the 2nd quarter worth approximately $29,987,000. Northern Trust Corp acquired a new position in shares of Artivion during the second quarter valued at $8,088,000. Goldman Sachs Group Inc. acquired a new position in shares of Artivion during the second quarter valued at $5,651,000. Kennedy Capital Management LLC increased its position in Artivion by 33.3% in the second quarter. Kennedy Capital Management LLC now owns 755,990 shares of the company’s stock worth $12,995,000 after purchasing an additional 188,712 shares during the period. Finally, UBS Group AG bought a new stake in Artivion during the 2nd quarter worth about $3,151,000. 83.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AORT shares. Needham & Company LLC increased their price target on shares of Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Stifel Nicolaus increased their target price on Artivion from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 16th.

Check Out Our Latest Report on Artivion

Artivion Company Profile

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

See Also

Insider Buying and Selling by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.